Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

Predicting the penetration of drugs across the human blood–brain barrier (BBB) is a significant challenge during their development. A variety of in vitro systems representing the BBB have been described, but the optimal use of these data in terms of extrapolation to human unbound brain concentration profiles remains to be fully exploited. Physiologically based pharmacokinetic (PBPK) modelling of drug disposition in the central nervous system (CNS) currently consists of fitting preclinical in vivo data to compartmental models in order to estimate the permeability and efflux of drugs across the BBB. The increasingly popular approach of using in vitro–in vivo extrapolation (IVIVE) to generate PBPK model input parameters could provide a more mechanistic basis for the interspecies translation of preclinical models of the CNS. However, a major hurdle exists in verifying these predictions with observed data, since human brain concentrations can’t be directly measured. Therefore a combination of IVIVE-based and empirical modelling approaches based on preclinical data are currently required. In this review, we summarise the existing PBPK models of the CNS in the literature, and we evaluate the current opportunities and limitations of potential IVIVE strategies for PBPK modelling of BBB penetration.

[1]  T. Terasaki,et al.  Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. , 2013, Journal of pharmaceutical sciences.

[2]  S-M Huang,et al.  Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position , 2013, Clinical pharmacology and therapeutics.

[3]  H. Sugimoto,et al.  Retrospective Analysis of P-Glycoprotein–Mediated Drug-Drug Interactions at the Blood-Brain Barrier in Humans , 2013, Drug Metabolism and Disposition.

[4]  E. D. Lange Utility of CSF in translational neuroscience , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  F. Theil,et al.  Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. , 2013, Molecular pharmaceutics.

[6]  K. Pang,et al.  Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.

[7]  R. Shawahna,et al.  Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. , 2012, Current drug metabolism.

[8]  W. Jusko,et al.  Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  B. Walther,et al.  Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. , 2012, Journal of pharmaceutical sciences.

[10]  A. Doran,et al.  An Evaluation of Using Rat-Derived Single-Dose Neuropharmacokinetic Parameters to Project Accurately Large Animal Unbound Brain Drug Concentrations , 2012, Drug Metabolism and Disposition.

[11]  A. Gupta,et al.  In vivo microdialysis in pharmacological studies of antibacterial agents in the brain. , 2012, British journal of anaesthesia.

[12]  A. Palmer,et al.  Translational CNS medicines research. , 2012, Drug discovery today.

[13]  R. Stratford,et al.  Microdialysis Evaluation of Clozapine and N-Desmethylclozapine Pharmacokinetics in Rat Brain , 2012, Drug Metabolism and Disposition.

[14]  Á. Kittel,et al.  Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Aleksandra Galetin,et al.  Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes , 2012, Drug Metabolism and Disposition.

[16]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[17]  Bart Ploeger,et al.  Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats , 2012, The AAPS Journal.

[18]  R. Stratford,et al.  Exploratory Translational Modeling Approach in Drug Development to Predict Human Brain Pharmacokinetics and Pharmacologically Relevant Clinical Doses , 2012, Drug Metabolism and Disposition.

[19]  E. Sands,et al.  Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates , 2012, Drug Metabolism and Disposition.

[20]  E. Kis,et al.  Efflux transporters in the blood–brain interfaces – in vitro and in vivo methods and correlations , 2012, Expert opinion on drug metabolism & toxicology.

[21]  François Bouzom,et al.  Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? , 2012, Biopharmaceutics & drug disposition.

[22]  R. Voskuyl,et al.  Alteration in P-glycoprotein Functionality Affects Intrabrain Distribution of Quinidine More Than Brain Entry—A Study in Rats Subjected to Status Epilepticus by Kainate , 2012, The AAPS Journal.

[23]  Yuichi Sugiyama,et al.  Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.

[24]  T. Terasaki,et al.  Blood-Brain Barrier (BBB) Pharmacoproteomics: Reconstruction of In Vivo Brain Distribution of 11 P-Glycoprotein Substrates Based on the BBB Transporter Protein Concentration, In Vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.

[25]  T. Terasaki,et al.  Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. , 2011, Journal of pharmaceutical sciences.

[26]  M. Danhof,et al.  Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. , 2011, Journal of pharmaceutical sciences.

[27]  T. Terasaki,et al.  Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. , 2011, Journal of pharmaceutical sciences.

[28]  Ignacio A. Romero,et al.  Development of a three-dimensional, all-human in vitro model of the blood–brain barrier using mono-, co-, and tri-cultivation Transwell models , 2011, Journal of Neuroscience Methods.

[29]  I. Wilhelm,et al.  Quinidine as an ABCB1 Probe for Testing Drug Interactions at the Blood–Brain Barrier , 2011, Journal of biomolecular screening.

[30]  C. Daumas-Duport,et al.  Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. , 2011, Molecular pharmaceutics.

[31]  D. Scott,et al.  Species Independence in Brain Tissue Binding Using Brain Homogenates , 2011, Drug Metabolism and Disposition.

[32]  A. Avdeef How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability? , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Jos H Beijnen,et al.  Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.

[34]  Alain Pruvost,et al.  In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. , 2011, Molecular pharmaceutics.

[35]  Takashi Suzuki,et al.  Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.

[36]  Ulf Bredberg,et al.  Measurement of Unbound Drug Exposure in Brain: Modeling of pH Partitioning Explains Diverging Results between the Brain Slice and Brain Homogenate Methods , 2011, Drug Metabolism and Disposition.

[37]  L. Helmdach,et al.  Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method , 2011, Drug Metabolism and Disposition.

[38]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[39]  A. Avdeef,et al.  Physicochemical Selectivity of the BBB Microenvironment Governing Passive Diffusion—Matching with a Porcine Brain Lipid Extract Artificial Membrane Permeability Model , 2011, Pharmaceutical Research.

[40]  Michael L Shuler,et al.  Murine in vitro model of the blood-brain barrier for evaluating drug transport. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[42]  Sagar Agarwal,et al.  The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[43]  J. Hakkarainen,et al.  Comparison of in vitro cell models in predicting in vivo brain entry of drugs. , 2010, International journal of pharmaceutics.

[44]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[45]  Stina Syvänen,et al.  Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. , 2010, Current topics in medicinal chemistry.

[46]  Sagar Agarwal,et al.  Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.

[47]  H. Kusuhara,et al.  Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone , 2010, Journal of Pharmacology and Experimental Therapeutics.

[48]  Santiago Vilar,et al.  Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. , 2010, Journal of molecular graphics & modelling.

[49]  Alex Avdeef,et al.  How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? , 2010, Journal of medicinal chemistry.

[50]  Jeih-San Liow,et al.  P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide , 2010, Journal of Nuclear Medicine.

[51]  Y. Sugiyama,et al.  Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates , 2010, Pharmaceutical Research.

[52]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[53]  P. Jeffrey,et al.  Assessment of the blood–brain barrier in CNS drug discovery , 2010, Neurobiology of Disease.

[54]  Alex Avdeef,et al.  Leakiness and Size Exclusion of Paracellular Channels in Cultured Epithelial Cell Monolayers–Interlaboratory Comparison , 2010, Pharmaceutical Research.

[55]  Jun Li,et al.  Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[56]  Susanne Winiwarter,et al.  Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. , 2009, Journal of medicinal chemistry.

[57]  Dominique Tytgat,et al.  Physiologically based pharmacokinetics (PBPK) , 2009, Drug metabolism reviews.

[58]  Li Di,et al.  Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. , 2009, Journal of pharmaceutical sciences.

[59]  Ulf Bredberg,et al.  Development of a High-Throughput Brain Slice Method for Studying Drug Distribution in the Central Nervous System , 2009, Drug Metabolism and Disposition.

[60]  Jeih-San Liow,et al.  Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein , 2009, Journal of Nuclear Medicine.

[61]  M. Monshouwer,et al.  Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid , 2009, Drug Metabolism and Disposition.

[62]  Jos H. Beijnen,et al.  Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.

[63]  B. Långström,et al.  Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport , 2009, Drug Metabolism and Disposition.

[64]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[65]  J. Schellens,et al.  The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib , 2009, Investigational New Drugs.

[66]  Jun Yu Li,et al.  Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination , 2009, Theoretical Biology and Medical Modelling.

[67]  J. C. Kalvass,et al.  Microdialysis Evaluation of Atomoxetine Brain Penetration and Central Nervous System Pharmacokinetics in Rats , 2009, Drug Metabolism and Disposition.

[68]  S. Krähenbühl,et al.  The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies , 2008, Journal of neurochemistry.

[69]  R N Gunn,et al.  Toward an improved prediction of human in vivo brain penetration , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[70]  T. Terasaki,et al.  Involvement of the Pyrilamine Transporter, a Putative Organic Cation Transporter, in Blood-Brain Barrier Transport of Oxycodone , 2008, Drug Metabolism and Disposition.

[71]  Jeih-San Liow,et al.  11C-Loperamide and Its N-Desmethyl Radiometabolite Are Avid Substrates for Brain Permeability-Glycoprotein Efflux , 2008, Journal of Nuclear Medicine.

[72]  Jashvant D Unadkat,et al.  In Vitro-to-in Vivo Prediction of P-glycoprotein-Based Drug Interactions at the Human and Rodent Blood-Brain Barrier , 2008, Drug Metabolism and Disposition.

[73]  Margareta Hammarlund-Udenaes,et al.  Blood–Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and Morphine , 2008, Anesthesiology.

[74]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[75]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.

[76]  Stina Syvänen,et al.  On The Rate and Extent of Drug Delivery to the Brain , 2007, Pharmaceutical Research.

[77]  U. Bredberg,et al.  In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids , 2007, Drug Metabolism and Disposition.

[78]  Anders Tunek,et al.  High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. , 2007, Journal of medicinal chemistry.

[79]  M. Danhof,et al.  Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat , 2007, Pharmaceutical Research.

[80]  P. Jeffrey,et al.  Challenges for blood–brain barrier (BBB) screening , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[81]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[82]  Phil Jeffrey,et al.  Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[83]  T. Terasaki,et al.  A functional in vitro model of rat blood–brain barrier for molecular analysis of efflux transporters , 2007, Brain Research.

[84]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[85]  Kjell Johnson,et al.  Porcine Brain Microvessel Endothelial Cells as an in Vitro Model to Predict in Vivo Blood-Brain Barrier Permeability , 2006, Drug Metabolism and Disposition.

[86]  U. Simonsson,et al.  In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics , 2006, Drug Metabolism and Disposition.

[87]  J. Cianfrogna,et al.  Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration , 2006, Drug Metabolism and Disposition.

[88]  Xingrong Liu,et al.  EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION , 2006, Drug Metabolism and Disposition.

[89]  Mark Muzi,et al.  Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data , 2006, Journal of Pharmacology and Experimental Therapeutics.

[90]  J. Scherrmann,et al.  Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide. , 2006, Life sciences.

[91]  Phil Jeffrey,et al.  Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[92]  Andreas Reichel,et al.  The role of blood-brain barrier studies in the pharmaceutical industry. , 2006, Current drug metabolism.

[93]  E. D. Lange,et al.  Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling , 2005, The AAPS Journal.

[94]  A. Palmer,et al.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery , 2005, NeuroRx.

[95]  K. Bernard,et al.  NEUROPHARMACOKINETICS OF A NEW α-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONIC ACID (AMPA) MODULATOR, S18986 [(S)-2,3-DIHYDRO-[3,4]CYCLOPENTANO-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE], IN THE RAT , 2005, Drug Metabolism and Disposition.

[96]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[97]  Ernesto Callegari,et al.  Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding , 2005, Journal of Pharmacology and Experimental Therapeutics.

[98]  Per Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .

[99]  Danny D Shen,et al.  Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.

[100]  E. Niclas Jonsson,et al.  An Integrated Model for the Analysis of Pharmacokinetic Data from Microdialysis Experiments , 2004, Pharmaceutical Research.

[101]  D. Hallifax,et al.  Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo , 2004, Pharmaceutical Research.

[102]  W. Pardridge,et al.  Log(BB), PS products and in silico models of drug brain penetration. , 2004, Drug discovery today.

[103]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002) , 2004, AAPS PharmSci.

[104]  Emi Nakashima,et al.  New approaches to in vitro models of blood-brain barrier drug transport. , 2003, Drug discovery today.

[105]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[106]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.

[107]  D. Scott,et al.  Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. , 2002, Journal of pharmaceutical and biomedical analysis.

[108]  M. R. Bouw,et al.  Blood‐brain barrier transport and brain distribution of morphine‐6‐glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling , 2001, British journal of pharmacology.

[109]  J. Platts,et al.  Correlation and prediction of a large blood-brain distribution data set--an LFER study. , 2001, European journal of medicinal chemistry.

[110]  M. R. Bouw,et al.  Modelling of the blood‐brain barrier transport of morphine‐3‐glucuronide studied using microdialysis in the rat: involvement of probenecid‐sensitive transport , 2000, British journal of pharmacology.

[111]  M. R. Bouw,et al.  Pharmacokinetic-Pharmacodynamic Modelling of Morphine Transport Across the Blood-Brain Barrier as a Cause of the Antinociceptive Effect Delay in Rats—A Microdialysis Study , 2000, Pharmaceutical Research.

[112]  M. Feher,et al.  A simple model for the prediction of blood-brain partitioning. , 2000, International journal of pharmaceutics.

[113]  R. Sawchuk,et al.  Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. , 1997, Journal of pharmaceutical sciences.

[114]  Y. Sugiyama,et al.  Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. , 1997, Journal of Pharmacology and Experimental Therapeutics.

[115]  Y. Sugiyama,et al.  Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. , 1997, The Journal of pharmacology and experimental therapeutics.

[116]  Malcolm Rowland,et al.  Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[117]  Y. Sugiyama,et al.  Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system☆ , 1997 .

[118]  L. Paalzow,et al.  Drug Equilibration Across the Blood—Brain Barrier-Pharmacokinetic Considerations Based on the Microdialysis Method , 1997, Pharmaceutical Research.

[119]  Yanfeng Wang,et al.  The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach , 1996, Pharmaceutical Research.

[120]  R. Sawchuk,et al.  Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. , 1995, Journal of pharmaceutical sciences.

[121]  W. Pardridge,et al.  Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.

[122]  R. Dedrick,et al.  Distributed model for drug delivery to CSF and brain tissue. , 1983, The American journal of physiology.

[123]  K. Pettigrew,et al.  Drug entry into the brain , 1979, Brain Research.

[124]  K D Pettigrew,et al.  Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.

[125]  C. Patlak,et al.  Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. , 1977, Cancer treatment reports.

[126]  J. Ghersi-Egea,et al.  In Vitro Models of the Blood–Cerebrospinal Fluid Barrier and Their Use in Neurotoxicological Research , 2011 .

[127]  H. Boriss Brain Availability Is the Key Parameter for Optimising the Permeability of Central Nervous System Drugs , 2010 .

[128]  A. Brancale,et al.  Homology Modelling of Human E1 Ubiquitin Activating Enzyme. , 2010, Letters in drug design & discovery.

[129]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[130]  F. Nelson,et al.  The Effect of Breast Cancer Resistance Protein ( Bcrp ) and P-glycoprotein ( Mdr 1 a / 1 b ) on the Brain Penetration of Flavopiridol , Gleevec , Prazosin and PF-407288 in Mice , 2009 .

[131]  Jiunn H. Lin,et al.  CSF as a surrogate for assessing CNS exposure: an industrial perspective. , 2008, Current drug metabolism.

[132]  P. Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[133]  Meihua Tu,et al.  Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[134]  Y. Deguchi Application of in vivo brain microdialysis to the study of blood-brain barrier transport of drugs. , 2002, Drug metabolism and pharmacokinetics.

[135]  Meindert Danhof,et al.  Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting , 2002, Clinical pharmacokinetics.

[136]  Thomas J. Raub,et al.  In vitro models for the blood-brain barrier. , 1998, Toxicology in vitro : an international journal published in association with BIBRA.

[137]  C S Patlak,et al.  Methods for Quantifying the transport of drugs across brain barrier systems. , 1981, Pharmacology & therapeutics.